Emergency Access to Insulin Act of 2023

To amend the Public Health Service Act to establish insulin assistance programs, and for other purposes. 1. Short title This Act may be cited as the Emergency Access to Insulin Act of 2023 2. Insulin assistance programs (a) In general Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq. 320C. Insulin assistance programs (a) Establishment of program of grants to States, Indian tribes, and tribal organizations (1) In general The Secretary shall, not later than 1 year after the date of enactment of this section, make grants to States, Indian tribes, and tribal organizations for the purpose of carrying out programs to assist eligible individuals in obtaining insulin in accordance with paragraph (4). (2) Grant and contract authority for States, Indian tribes, and tribal organizations (A) In general A State, Indian tribe, or tribal organization receiving a grant under paragraph (1) may, subject to subparagraph (B), expend the grant to carry out the purpose described in such paragraph through grants or contracts to public or private entities, including local governments. (B) Certain applications If a nonprofit private entity and a private entity that is not a nonprofit entity both submit applications to a State, Indian tribe, or tribal organization to receive an award of a grant or contract under subparagraph (A), the State, Indian tribe, or tribal organization shall give priority to the application submitted by the nonprofit private entity in any case in which the State, Indian tribe, or tribal organization determines that the quality of such application is equivalent to the quality of the application submitted by the other private entity. (3) Allotment Each State, Indian tribe, or tribal organization that applies for a grant in accordance with subsection (e) shall receive a grant under this section in an amount that is equal to the sum of— (A) a minimum amount determined by the Secretary; and (B) an additional amount based on criteria established by the Secretary, which may include the ability of the State, Indian tribe, or tribal organization to successfully assist individuals in seeking eligibility for Federal or State-funded programs as described in paragraph (4)(A)(ii)(II). (4) Program components (A) In general A State, Indian tribe, or tribal organization carrying out a program supported by a grant under this subsection— (i) shall use the grant funds to— (I) issue insulin cards to eligible individuals in accordance with subparagraph (B); and (II) enter into agreements with pharmacies— (aa) for such pharmacies to fill prescriptions for individuals displaying valid insulin cards that are issued in accordance with subparagraph (B) at no cost to such individuals; and (bb) for the State, Indian tribe, or tribal organization to pay such pharmacies for insulin filled for a prescription described in item (aa); and (ii) may use the grant funds to— (I) purchase insulin; or (II) assist individuals in seeking eligibility for Federal or State-funded programs which may provide coverage for insulin or otherwise assist such individuals in obtaining insulin. (B) Insulin cards (i) Application An eligible individual seeking an insulin card through a program supported by a grant under this subsection shall submit an application to the State, Indian tribe, or tribal organization receiving the grant, at such time, in such manner, and containing such information as the State, Indian tribe, or tribal organization may reasonably require for purposes of this subsection, including— (I) documentation indicating proof of— (aa) in the case of a grant awarded to a State, residency in the State; (bb) in the case of a grant awarded to an Indian tribe, membership in the Indian tribe; or (cc) in the case of a grant awarded to a tribal organization, membership in the Indian tribe or Indian community served by the tribal organization; (II) a prescription for insulin that is prescribed to the individual; (III) a statement that, to the best of the individual's knowledge, the individual is an uninsured individual or an underinsured individual; and (IV) if the individual is an underinsured individual, the name of the high-deductible health plan in which the individual is enrolled and any unique identifier of the plan, such as a policy number. (ii) Initial card (I) In general A State, Indian tribe, or tribal organization carrying out a program supported by a grant under this subsection shall issue an initial insulin card to each individual that submits an application to the State, Indian tribe, or tribal organization meeting the requirements under clause (i). (II) Timing A State, Indian tribe, or tribal organization that receives an application under clause (i) from an individual shall issue an initial insulin card to such individual not later than 5 business days after receiving such application. (III) Supply An initial insulin card issued to an individual under this clause shall be valid for an approximate 7-day supply of insulin that is appropriate for the individual based on the prescription for the individual provided in the application under clause (i) and packaging and processing practices for insulin. (iii) 3-month cards Not later than 12 business days after an individual submits an application under clause (i) to a State, Indian tribe, or tribal organization, the State, Indian tribe, or tribal organization shall— (I) determine whether the individual is an eligible individual; and (II) if the individual is an eligible individual, issue the individual an insulin card that is valid for an approximate 90-day supply of insulin that is appropriate for the individual based on the prescription provided in the application under clause (i) and packaging and processing practices for insulin. (iv) Renewal of cards (I) 3-month cards An eligible individual that is issued an insulin card under clause (iii) may apply to renew such card in accordance with a process established by the State, Indian tribe, or tribal organization. (II) Limitation An individual that submits an application under clause (i) and is denied an insulin card under clause (ii) or (iii) may not submit another application under clause (i) for the 1-year period beginning on the date on which the individual is denied such card. (b) Requirement of matching funds (1) In general The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees, with respect to the costs to be incurred by the State, Indian tribe, or tribal organization in carrying out the purpose described in subsection (a)(1), to make available non-Federal contributions (in cash or in kind under paragraph (2)) toward such costs in an amount equal to not less than $1 for each $3 of Federal funds provided in the grant. Such contributions may be made directly or through donations from public or private entities. (2) Determination of amount of non-federal contribution (A) In general Non-Federal contributions required in paragraph (1) may be in cash or in kind, fairly evaluated, including equipment or services (and excluding indirect or overhead costs). Amounts provided by the Federal Government, or services assisted or subsidized to any significant extent by the Federal Government, may not be included in determining the amount of such non-Federal contributions. (B) Maintenance of effort In making a determination of the amount of non-Federal contributions for purposes of paragraph (1), the Secretary may include only non-Federal contributions in excess of the average amount of non-Federal contributions made by the State, Indian tribe, or tribal organization involved toward the purpose described in subsection (a)(1) for the 2-year period preceding the first fiscal year for which the State, Indian tribe, or tribal organization is applying to receive a grant under subsection (a). (C) Inclusion of relevant non-federal contributions for medicaid In making a determination of the amount of non-Federal contributions for purposes of paragraph (1), the Secretary shall, subject to subparagraphs (A) and (B) of this paragraph, include any non-Federal amounts expended pursuant to title XIX of the Social Security Act by the State, Indian tribe, or tribal organization related to insulin dispensed to individuals eligible for medical assistance under such title. (c) Additional required agreements (1) Statewide provision of services (A) In general The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees that services and activities under the grant will be made available throughout the State (including availability to members of any Indian tribe or tribal organization in the State), Indian tribe, or tribal organization. (B) Waiver (i) In general The Secretary may waive the requirement established in subparagraph (A) for a State, Indian tribe, or tribal organization if the Secretary determines that compliance by the State, Indian tribe, or tribal organization with the requirement would result in an inefficient allocation of resources with respect to carrying out the purpose described in subsection (a)(1). (ii) Indian tribes and tribal organizations If an Indian tribe or tribal organization is receiving a grant under subsection (a) and the State in which the tribe or organization is located is receiving a grant under subsection (a), the requirement under subparagraph (A) for the State regarding availability to the tribe or organization is deemed to have been waived under this subparagraph. (2) Relationship to items and services under other programs (A) In general The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees that the grant will not be expended to make payment for any item or service to the extent that payment has been made, or can reasonably be expected to be made, with respect to such item or service— (i) except as provided in subparagraph (B), under any State compensation program, under an insurance policy, or under any Federal or State health benefits program; or (ii) by an entity that provides health services on a prepaid basis. (B) Exception The requirement under subparagraph (A)(i) shall not apply with respect to coverage under a high-deductible health plan. (3) Limitation on administrative expenses The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees that not more than 10 percent of the grant will be expended for administrative expenses with respect to the grant. (4) Records and audits The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees that— (A) the State, Indian tribe, or tribal organization will establish such fiscal control and fund accounting procedures as may be necessary to ensure the proper disbursal of, and accounting for, amounts received by the State, Indian tribe, or tribal organization under such subsection; (B) the State, Indian tribe, or tribal organization will keep such records as the Secretary shall prescribe, including— (i) records that fully disclose— (I) the amount and disposition by the State, Indian tribe, or tribal organization of the proceeds of such grant; (II) the total cost of the project or undertaking intended to be carried out through the grant; and (III) the amount of that portion of the cost of the project or undertaking supplied by sources other than the grant; and (ii) such other records as the Secretary determines appropriate for facilitating an effective audit of grants awarded under this section; and (C) upon request, the State, Indian tribe, or tribal organization will provide records maintained pursuant to subparagraphs (A) and (B) to the Secretary or the Comptroller General of the United States for purposes of auditing the expenditures by the State, Indian tribe, or tribal organization of the grant. (5) Reports (A) Reports to the Secretary The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees to submit to the Secretary such reports as the Secretary may require with respect to the grant, including a report on— (i) the types of problems and inquiries encountered by individuals applying for or receiving insulin through a program supported by such grant; (ii) the number of insulin products dispensed through such program and the unit costs for those products during the period covered by the report; (iii) the number of pharmacies participating in the program during the period covered by the report; (iv) summary data on the individuals applying for or receiving insulin through the program; and (v) any other information the Secretary shall determine necessary to provide oversight of the grants made under this section. (B) High-deductible health plans The Secretary may not make a grant under subsection (a) unless the State, Indian tribe, or tribal organization involved agrees to, as soon as practicable after each time the State, Indian tribe, or tribal organization provides payment to a pharmacy for insulin for an underinsured individual, submit to the high-deductible health plan in which the individual is enrolled information on the amount of such payment in order for such plan to comply with the requirements under section 2710. (d) Description of intended uses of grant The Secretary may not make a grant under subsection (a) unless— (1) the State, Indian tribe, or tribal organization involved submits to the Secretary a description of the purposes for which the State, Indian tribe, or tribal organization intends to expend the grant; (2) the description identifies the populations, areas, and localities in the State, or under the jurisdiction of the Indian tribe or tribal organization, with a need for a program to assist individuals in obtaining insulin in accordance with subsection (a); (3) the description provides information relating to the services and activities to be provided, including a description of the manner in which the services and activities will be coordinated with any similar services or activities of public or private entities; and (4) the description provides assurances that the grant funds will be used in the most cost-effective manner. (e) Requirement of submission of application The Secretary may not make a grant under subsection (a) unless an application for the grant is submitted to the Secretary, the application contains the description of intended uses required under subsection (d), and the application is in such form, is made in such manner, and contains such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section. (f) Technical assistance and provision of supplies and services in lieu of grant funds (1) Technical assistance The Secretary may provide training and technical assistance with respect to the planning, development, and operation of any program or service carried out pursuant to subsection (a). The Secretary may provide such technical assistance directly or through grants to, or contracts with, public or private entities. (2) Provision of supplies and services in lieu of grant funds (A) In general Upon the request of a State, Indian tribe, or tribal organization receiving a grant under subsection (a), the Secretary may, subject to subparagraph (B), provide supplies, equipment, and services for the purpose of aiding the State, Indian tribe, or tribal organization in carrying out such subsection and, for such purpose, may detail to the State, Indian tribe, or tribal organization any officer or employee of the Department of Health and Human Services. (B) Corresponding reduction in payments With respect to a request described in subparagraph (A), the Secretary shall reduce the amount of payments under the grant under subsection (a) to the State, Indian tribe, or tribal organization involved by an amount equal to the costs of detailing personnel (including pay, allowances, and travel expenses) and the fair market value of any supplies, equipment, or services provided by the Secretary. The Secretary shall, for the payment of expenses incurred in complying with such request, expend the amounts withheld. (g) Evaluations and reports (1) Evaluations The Secretary shall, directly or through contracts with public or private entities, provide for annual evaluations of programs carried out pursuant to subsection (a). Such evaluations shall include evaluations of— (A) the extent to which States, Indian tribes, and tribal organizations carrying out such programs are in compliance with subsection (a) and with subsection (c)(1); and (B) the extent to which each State, Indian tribe, or tribal organization receiving a grant under this section is in compliance with subsection (b), including identification of— (i) the amount of the non-Federal contributions by the State, Indian tribe, or tribal organization for the preceding fiscal year, disaggregated according to the source of the contributions; and (ii) the proportion of such amount of non-Federal contributions relative to the amount of Federal funds provided through the grant to the State, Indian tribe, or tribal organization for the preceding fiscal year. (2) Reports to Congress The Secretary shall, not later than 1 year after the date of enactment of the Emergency Access to Insulin Act of 2023 (h) Funding for general program (1) Authorization of appropriations For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary. (2) Set-aside for technical assistance and provision of supplies and services Of the amounts appropriated under paragraph (1) for a fiscal year, the Secretary shall reserve not more than 20 percent for carrying out subsection (f). (i) Sunset The authority to award grants under subsection (a) shall be effective beginning on the date of enactment of the Emergency Access to Insulin Act of 2023 (j) Definitions For purposes of this section: (1) Eligible individual The term eligible individual (A) (i) in the case of a grant to a State, who is a resident of the State; (ii) in the case of a grant to an Indian tribe, who is a member of such tribe; or (iii) in the case of a grant to a tribal organization, who is a member of the Indian tribe or Indian community served by the tribal organization; and (B) who has a valid prescription for insulin that is prescribed to such individual. (2) Group health insurance coverage; group health plan; health insurance issuer The terms group health insurance coverage group health plan health insurance issuer (3) High-deductible health plan The term high-deductible health plan (4) Indian tribe The term Indian tribe 25 U.S.C. 1603 (5) Individual health insurance coverage The term individual health insurance coverage (6) Tribal organization The term tribal organization 25 U.S.C. 1603 (7) Underinsured individual The term underinsured individual (8) Uninsured individual The term uninsured individual section 5000A(f)(1) (9) Urban Indian organization The term urban Indian organization . (b) Exempting prices used under an insulin assistance program from best price and average manufacturer price under the Medicaid drug rebate program Section 1927 of the Social Security Act ( 42 U.S.C. 1396r–8 (1) in subsection (c)(1)(C)(i)(III), by inserting or under an insulin assistance program supported under section 320C of the Public Health Service Act State pharmaceutical assistance program (2) in subsection (k)(1)(B)(i)— (A) in subclause (IV), by inserting a semicolon at the end; (B) in subclause (VII), by striking ; and (C) in subclause (VIII), by striking the period at the end and inserting ; and (D) by adding at the end the following new subclause: (IX) any prices used under an insulin assistance program supported under section 320C of the Public Health Service Act. . (c) Deductibles for underinsured individuals participating in insulin assistance programs Subpart I of part A of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg et seq. 2710. Deductibles and other out-of-pocket expenses for underinsured individuals participating in insulin assistance programs (a) In general A group health plan that is a high-deductible health plan and a health insurance issuer offering a high-deductible health plan shall, with respect to any individual who is enrolled in such plan and obtains insulin during a plan year through an insulin card issued to the individual by a State, Indian tribe, or tribal organization carrying out an insulin assistance program under section 320C, count the amount the State, Indian tribe, or tribal organization pays a pharmacy for insulin for such individual for such plan year towards any deductible or other out-of-pocket expenses required to be paid under the plan. (b) High-Deductible health plan For purposes of this section, the term high-deductible health plan . 3. Annual fees applicable to insulin manufacturers (a) Definitions For purposes of this section: (1) Annual payment date The term annual payment date (2) Covered entity The term covered entity (A) is the holder of an application approved under subsection (c) of section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 42 U.S.C. 262 (B) during the preceding calendar year, manufactured any insulin product that was sold in commerce and covered by a Federal health program at least once during such preceding calendar year. (3) Inspector General The term Inspector General (4) Secretary The term Secretary (b) Imposition of fee Each covered entity for a calendar year, beginning in 2024 and ending in 2028, shall pay to the Secretary not later than the annual payment date of such calendar year a fee in an amount determined under subsection (c). (c) Amount of fees (1) Total amount The Secretary shall ensure that the total amount in fees assessed under subsection (b)— (A) for calendar year 2024, equals the total amount the Secretary estimates as the total expenditures for carrying out section 320C of the Public Health Service Act for such calendar year; and (B) for each of calendar years 2025 through 2028, equals the total amount of expenditures the Secretary determines for carrying out such section for the preceding calendar year. (2) Determination of fees for each manufacturer (A) Formula With respect to each covered entity, the fee under this section for a calendar year shall be equal to an amount that bears the same ratio to the total amount assessed under subsection (b) for such year as the covered entity's sales of insulin products taken into account during the preceding calendar year bears to the aggregate sales of insulin products of all covered entities taken into account during such preceding calendar year. (B) Sales of insulin products (i) In general For purposes of this paragraph, the sales of insulin products taken into account during any calendar year with respect to any covered entity shall be determined based on the total number of units of the insulin product which were sold in commerce in the preceding calendar year based on— (I) for a fee assessed for calendar year 2024, information obtained by the Secretary under clause (ii); and (II) for a fee assessed for each of calendar years 2025 through 2028, the information provided in the annual reports issued by the Inspector General and made public under section 4(e)(1). (ii) Fees assessed for calendar year 2024 For purposes of clause (i)(I), the Secretary shall require each covered entity to submit to the Secretary information on the total number of units of the insulin product manufactured by the entity that were sold in commerce in calendar year 2023. (d) Deposit The Secretary shall deposit amounts received through fees assessed under subsection (b) into the general fund of the Treasury. (e) Enforcement The Secretary may bring an action in any court of competent jurisdiction to recover the amount of any fee that is assessed under subsection (b) for a calendar year and not paid by the annual payment date. 4. Identification of insulin price spikes; application of excise tax (a) Definitions In this section: (1) Applicable entity The term applicable entity 21 U.S.C. 355 42 U.S.C. 262 (2) Commerce The term commerce 15 U.S.C. 44 (3) Inspector General The term Inspector General (4) Price spike (A) In general The term price spike (B) Price spike percentage The term price spike percentage (i) the wholesale acquisition cost of an insulin product in commerce for the calendar year; exceeds (ii) the wholesale acquisition cost of such insulin product in commerce for the calendar year preceding such year. (C) Applicable price increase allowance The term applicable price increase allowance section 1(f)(6) (5) Price spike revenue (A) In general The term price spike revenue (i) the gross price spike revenue, minus (ii) the adjustment amount. (B) Gross price spike revenue The term gross price spike revenue (i) an amount equal to the difference between clause (i) of paragraph (4)(B) and clause (ii) of such paragraph; and (ii) the total number of units of the insulin product which were sold in commerce in such calendar year. (C) Adjustment amount The term adjustment amount (b) Submission by pharmaceutical companies of information to Inspector General (1) In general For each insulin product, the applicable entity shall submit to the Inspector General a quarterly report that includes each of the following: (A) For each insulin product of the applicable entity— (i) the total number of units of the insulin product which were sold in commerce in the preceding calendar quarter; (ii) the average and median wholesale acquisition cost per unit of such insulin product in commerce in the preceding calendar quarter, disaggregated by month; and (iii) the gross revenues from sales of such insulin product in commerce in the preceding calendar quarter. (B) Such information related to increased input costs or public health considerations as the applicable entity may wish the Inspector General to consider in making a determination under clause (ii) of subsection (c)(2)(B) or an assessment in clause (iii) of such subsection for the preceding calendar quarter. (C) Such information related to any anticipated increased input costs for the subsequent calendar quarter as the applicable entity may wish the Inspector General to consider in making a determination under clause (ii) of subsection (c)(2)(B) or an assessment in clause (iii) of such subsection for such calendar quarter. (2) Penalty for failure to submit (A) In general An applicable entity described in paragraph (1) that fails to submit information to the Inspector General regarding an insulin product, as required by such paragraph, before the date specified in paragraph (3) shall be liable for a civil penalty, as determined under subparagraph (B). (B) Amount of penalty The amount of the civil penalty shall be equal to the product of— (i) an amount, as determined appropriate by the Inspector General, which is— (I) not less than 0.5 percent of the gross revenues from sales of the insulin product described in subparagraph (A) for the preceding calendar year; and (II) not greater than 1 percent of the gross revenues from sales of such insulin product for the preceding calendar year; and (ii) the number of days in the period between— (I) the applicable date specified in paragraph (3); and (II) the date on which the Inspector General receives the information described in paragraph (1) from the applicable entity. (3) Submission deadline An applicable entity shall submit each quarterly report described in paragraph (1) not later than January 17, April 18, June 15, and September 15 of each calendar year. (c) Assessment by Inspector General (1) In general Not later than the last day in February of each year, the Inspector General, in consultation with other relevant Federal agencies (including the Federal Trade Commission), shall— (A) complete an assessment of the information the Inspector General received pursuant to subsection (b)(1) with respect to sales of insulin products in the preceding calendar year; and (B) in the case of any insulin product which satisfies the conditions described in paragraph (1) or (2) of subsection (d), submit a recommendation to the Secretary of Health and Human Services that such insulin product be exempted from application of the tax imposed under section 4191 (2) Elements The assessment required by paragraph (1)(A) shall include each of the following: (A) Identification of each price spike relating to an insulin product in the preceding calendar year. (B) For each price spike identified under subparagraph (A)— (i) a determination of the price spike revenue; (ii) a determination regarding the accuracy of the information submitted by the applicable entity regarding increased input costs; and (iii) an assessment of the rationale of the applicable entity for the price spike. (d) Exemption of certain insulin products (1) In general The Secretary of Health and Human Services, upon recommendation of the Inspector General pursuant to subsection (c)(1)(B), may exempt any insulin product which has been subject to a price spike during the preceding calendar year from application of the tax imposed under section 4191 (2) Clarification In considering, under paragraph (1), information submitted pursuant to subsection (b)(1)(B), the Secretary— (A) has the discretion to determine that such information does not warrant a for-cause price increase exemption; and (B) shall exclude from such consideration any information submitted by the applicable entity threatening to curtail or limit production of the insulin product if the Secretary does not grant an exemption from the application of the tax under section 4191 (e) Reports by Inspector General (1) Public report (A) In general Not later than the last day in February of each year, subject to subparagraph (C), the Inspector General shall issue a report containing the information described in subparagraph (B) to be made available to the public, including on the internet website of the Inspector General. (B) Contents The report issued under subparagraph (A) shall include each of the following: (i) The information received under subsection (b)(1) with respect to the preceding calendar year. (ii) The price spikes identified under subparagraph (A) of subsection (c)(2). (iii) The price spike revenue determinations made under subparagraph (B)(i) of such subsection. (iv) The determinations and assessments made under clauses (ii) and (iii) of subparagraph (B) of such subsection. (C) Proprietary information The Inspector General shall ensure that any information made public in accordance with subparagraph (A) excludes trade secrets and confidential commercial information. (2) Report to Internal Revenue Service (A) In general Subject to subparagraph (C), not later than the last day in February of each year, the Inspector General shall transmit to the Internal Revenue Service a report on the findings of the Inspector General with respect to the information the Inspector General received under subsection (b)(1) with respect to the preceding calendar year and the assessment carried out by the Inspector General under subsection (c)(1)(A) with respect to such information. (B) Contents The report transmitted under subparagraph (A) shall include the information described in paragraph (1)(B). (C) Notice and opportunity for hearing (i) In general No report shall be transmitted to the Internal Revenue Service under subparagraph (A) with respect to an insulin product unless the Inspector General has provided the applicable entity with— (I) the assessment of such insulin product under subsection (c)(1)(A); and (II) notice of their right to a hearing in regards to such assessment. (ii) Notice The notice required under clause (i) shall be provided to the applicable entity not later than 30 days after completion of the assessment under subsection (c)(1)(A). (iii) Request for hearing Subject to clause (v), an applicable entity may request a hearing before the Secretary of Health and Human Services not later than 30 days after the date on which the notice under clause (ii) is received. (iv) Completion of hearing In the case of an applicable entity which requests a hearing pursuant to clause (iii), the Secretary of Health and Human Services shall, not later than 12 months after the date on which the assessment under subsection (c)(1)(A) was completed by the Inspector General— (I) make a final determination in regards to the accuracy of such assessment; and (II) provide the report described in subparagraph (B) to the Internal Revenue Service. (v) Limitation An applicable entity may request a hearing under clause (iii) with respect to a particular insulin product only once within a 5-year period. (f) Notification The Secretary of the Treasury shall notify, at such time and in such manner as the Secretary of the Treasury shall provide, each applicable entity in regard to any insulin product which has been determined to have been subject to a price spike during the preceding calendar year and the amount of the tax imposed on such applicable entity pursuant to section 4191 (g) Excise tax on insulin products subject to price spikes (1) In general Chapter 32 E Certain insulin products Sec. 4191. Insulin products subject to price spikes. 4191. Insulin products subject to price spikes (a) Imposition of tax (1) In general Subject to paragraph (3), for each taxable insulin product sold by an applicable entity during the calendar year, there is hereby imposed on such entity a tax equal to the greater of— (A) the annual price spike tax for such insulin product, or (B) subject to paragraph (2), the cumulative price spike tax for such insulin product. (2) Limitation In the case of a taxable insulin product for which the applicable period (as determined under subsection (c)(2)(E)(i)) is less than 2 calendar years, the cumulative price spike tax shall not apply. (3) Exemption For any calendar year in which the Secretary of Health and Human Services has provided an exemption for a taxable insulin product pursuant to section 4(d) of the Emergency Access to Insulin Act of 2023 (b) Annual price spike tax (1) In general The amount of the annual price spike tax shall be equal to the applicable percentage of the price spike revenue received by the applicable entity on the sale of the taxable insulin product during the calendar year. (2) Applicable percentage For purposes of paragraph (1), the applicable percentage shall be equal to— (A) in the case of a taxable insulin product which has been subject to a price spike percentage greater than the applicable price increase allowance (as defined in section 4(a)(4)(C) of the Emergency Access to Insulin Act of 2023 (B) in the case of a taxable insulin product which has been subject to a price spike percentage equal to or greater than 15 percent but less than 20 percent, 75 percent, and (C) in the case of a taxable insulin product which has been subject to a price spike percentage equal to or greater than 20 percent, 100 percent. (c) Cumulative price spike tax (1) In general The amount of the cumulative price spike tax shall be equal to the applicable percentage of the cumulative price spike revenue received by the applicable entity on the sale of the taxable insulin product during the calendar year. (2) Applicable percentage (A) In general For purposes of paragraph (1), the applicable percentage shall be equal to— (i) in the case of a taxable insulin product which has been subject to a cumulative price spike percentage greater than the cumulative price increase allowance but less than the first multi-year percentage, 50 percent, (ii) in the case of a taxable insulin product which has been subject to a cumulative price spike percentage equal to or greater than the first multi-year percentage but less than the second multi-year percentage, 75 percent, and (iii) in the case of a taxable insulin product which has been subject to a cumulative price spike percentage equal to or greater than the second multi-year percentage, 100 percent. (B) Cumulative price spike percentage The cumulative price spike percentage is the percentage (if any) by which— (i) the wholesale acquisition cost of the taxable insulin product in commerce for the preceding calendar year, exceeds (ii) the wholesale acquisition cost of such insulin product in commerce for the base year. (C) Cumulative price increase allowance For purposes of clause (i) of subparagraph (A), the cumulative price increase allowance for any calendar year is the percentage (rounded to the nearest one-tenth of 1 percent) by which the C–CPI–U (as defined in section 1(f)(6)) for that year exceeds the C–CPI–U for the base year. (D) Multi-year percentages For purposes of subparagraph (A), the first multi-year percentage and second multi-year percentage shall be determined in accordance with the following table: Number of years in applicable period First Second 2 years 17.5 22.5 3 years 20.0 25.0 4 years 22.5 27.5 5 years 25.0 30.0. (E) Applicable period and base year (i) Applicable period The applicable period shall be the lesser of— (I) the 5 preceding calendar years, (II) all calendar years beginning after the date of enactment of this section, or (III) all calendar years in which the taxable insulin product was sold in commerce. (ii) Base year The base year shall be the calendar year immediately preceding the applicable period. (3) Cumulative price spike revenue For purposes of paragraph (1), the cumulative price spike revenue for any taxable insulin product shall be an amount equal to— (A) an amount equal to the product of— (i) an amount (not less than zero) equal to— (I) the wholesale acquisition cost of such insulin product in commerce for the preceding calendar year, minus (II) the wholesale acquisition cost of such insulin product in commerce for the base year, and (ii) the total number of units of such insulin product which were sold in commerce in the preceding calendar year, minus (B) an amount equal to the sum of the adjustment amounts, if any, determined under section 4(a)(5)(C) of the Emergency Access to Insulin Act of 2023 (d) Definitions For purposes of this section— (1) Taxable insulin product The term taxable insulin product Emergency Access to Insulin Act of 2023 (2) Other terms The terms applicable entity price spike price spike percentage price spike revenue Emergency Access to Insulin Act of 2023 . (2) Clerical amendment The table of subchapters for chapter 32 SUBCHAPTER E—Certain insulin products . (3) Effective date The amendments made by this subsection shall apply to sales after the date of the enactment of this Act. 5. Biological product exclusivity (a) In general Section 351(k)(7)(A) of the Public Health Service Act ( 42 U.S.C. 262(k)(7)(A) 12 years 7 years (b) Conforming amendments Paragraphs (2)(A) and (3)(A) of section 351(m) of the Public Health Service Act ( 42 U.S.C. 262(m) 12 years 7 years

Summary: Emergency Access to Insulin Act of 2023 This bill reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin. Specifically, the bill requires the Department of Health and Human Services (HHS) to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual&rsquo;s health plan deductible or other out-of-pocket expenses required under the plan. Further, HHS must collect annual fees from insulin manufacturers, based on each manufacturer&rsquo;s market share, equal to the total estimated expenditures under the insulin grants program. Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.